Myriad and Cephalon Enter Into Companion Diagnostic Agreement

Myriad Genetics, Inc.

announced today that it has signed an agreement with Cephalon

to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. "We are extremely pleased to be working with Cephalon, one of the world's leading healthcare companies, on this exciting new clinical study," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "This collaboration is a further demonstration of Myriad's commitment to and leadership in the field of companion diagnostics." Under the agreement, Myriad will assess the BRCA status in patients prior to being enrolled in the study. Myriad has entered into similar agreements with Abbott Pharmaceuticals, Astra Zeneca and BioMarin Pharmaceuticals to provide companion diagnostic testing with the BRACAnalysis® test for clinical trial enrollment.